Your browser doesn't support javascript.
loading
Frequent HPV-independent p16/INK4A overexpression in head and neck cancer.
Lechner, Matt; Chakravarthy, Ankur R; Walter, Vonn; Masterson, Liam; Feber, Andrew; Jay, Amrita; Weinberger, Paul M; McIndoe, Richard A; Forde, Cillian T; Chester, Kerry; Kalavrezos, Nicholas; O'Flynn, Paul; Forster, Martin; Jones, Terry M; Vaz, Francis M; Hayes, D Neil; Fenton, Tim R.
Affiliation
  • Lechner M; UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, United Kingdom; Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London NW1 2PG, United Kingdom.
  • Chakravarthy AR; UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, United Kingdom.
  • Walter V; Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, United States; UNC Lineberger Comprehensive Cancer Center, School of Medicine, UNC-Chapel Hill, NC, United States.
  • Masterson L; Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, United Kingdom.
  • Feber A; Division of Surgery & Interventional Science, University College London,London, United Kingdom.
  • Jay A; Department of Histopathology, University College London Hospitals NHS Trust, Euston Road, London NW1 2PG, United Kingdom.
  • Weinberger PM; Center for Biotechnology and Genomic Medicine, Department of Otolaryngology, and Georgia Regents Cancer Center, Georgia Regents University, Augusta, GA, United States.
  • McIndoe RA; Center for Biotechnology and Genomic Medicine, Department of Otolaryngology, and Georgia Regents Cancer Center, Georgia Regents University, Augusta, GA, United States.
  • Forde CT; Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London NW1 2PG, United Kingdom.
  • Chester K; UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, United Kingdom.
  • Kalavrezos N; Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London NW1 2PG, United Kingdom.
  • O'Flynn P; Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London NW1 2PG, United Kingdom.
  • Forster M; UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, United Kingdom; Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London NW1 2PG, United Kingdom.
  • Jones TM; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Vaz FM; Head and Neck Centre, University College London Hospitals NHS Trust, Euston Road, London NW1 2PG, United Kingdom.
  • Hayes DN; Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, United States. Electronic address: hayes@med.unc.edu.
  • Fenton TR; School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom. Electronic address: t.fenton@kent.ac.uk.
Oral Oncol ; 83: 32-37, 2018 08.
Article in En | MEDLINE | ID: mdl-30098776
ABSTRACT

OBJECTIVES:

p16INK4A (p16) is the most widely used clinical biomarker for Human Papillomavirus (HPV) in head and neck squamous cell cancer (HNSCC). HPV is a favourable prognostic marker in HNSCC and is used for patient stratification. While p16 is a relatively accurate marker for HPV within the oropharynx, recent reports suggest it may be unsuitable for use in other HNSCC subsites, where a smaller proportion of tumors are HPV-driven. MATERIALS AND

METHODS:

We integrated reverse phase protein array (RPPA) data for p16 with HPV status based on detection of viral transcripts by RNA-seq in a set of 210 HNSCCs profiled by The Cancer Genome Atlas project. Samples were queried for alterations in CDKN2A, and other pathway genes to investigate possible drivers of p16 expression.

RESULTS:

While p16 levels as measured by RPPA were significantly different by HPV status, there were multiple HPV (-) samples with similar expression levels of p16 to HPV (+) samples, particularly at non-oropharyngeal subsites. In many cases, p16 overexpression in HPV (-) tumors could not be explained by mutation or amplification of CDKN2A or by RB1 mutation. Instead, we observed enrichment for inactivating mutations in the histone H3 lysine 36 methyltransferase, NSD1 in HPV (-)/p16-high tumors.

CONCLUSIONS:

RPPA data suggest high p16 protein expression in many HPV (-) non-oropharyngeal HNSCCs, limiting its potential utility as an HPV biomarker outside of the oropharynx. HPV-independent overexpression of wild-type p16 in non-oropharyngeal HNSCC may be linked to global deregulation of chromatin state by inactivating mutations in NSD1.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Cyclin-Dependent Kinase Inhibitor p16 / Alphapapillomavirus / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Oral Oncol Year: 2018 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Cyclin-Dependent Kinase Inhibitor p16 / Alphapapillomavirus / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Oral Oncol Year: 2018 Document type: Article